Journal Article
. 2018 Dec; 145(1):274-283.
doi: 10.1002/ijc.32093.

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure

Irene E G van Hellemond 1 Ingeborg J H Vriens 1 Petronella G M Peer 2 Astrid C P Swinkels 3 Carolien H Smorenburg 4 Caroline M Seynaeve 5 Maurice J C van der Sangen 6 Judith R Kroep 7 Hiltje de Graaf 8 Aafke H Honkoop 9 Frans L G Erdkamp 10 Franchette W P J van den Berkmortel 11 Maaike de Boer 1 Wilfred K de Roos 12 Sabine C Linn 13 Alexander L T Imholz 14 Vivianne C G Tjan-Heijnen 1 Dutch Breast Cancer Research Group (BOOG)  
  • PMID: 30588619
  •     36 References


The DATA study (NCT00301457) compared 6 and 3 years of anastrozole in postmenopausal women with hormone receptor-positive early breast cancer after 2-3 years of tamoxifen. Patients with chemotherapy-induced ovarian function failure (CIOFF) were also eligible, but could be at risk of ovarian function recovery (OFR). The current analysis compared the survival of women with CIOFF with definitely postmenopausal women and examined the influence of OFR on survival. Therefore, we selected patients from the DATA study aged 45-57 years at randomization who had received (neo)adjuvant chemotherapy. They were classified by reversibility of postmenopausal status: possibly reversible in case of CIOFF (n = 395) versus definitely postmenopausal (n = 261). The former were monitored by E2 measurements for OFR. The occurrence of OFR was incorporated as a time-dependent covariate in a Cox-regression model for calculating the hazard ratio (HR). We used the landmark method to calculate residual 5-year survival rates. When comparing CIOFF women with definitely postmenopausal women, the survival was not different. Among CIOFF women with available E2 follow-up values (n = 329), experiencing OFR (n = 39) had an unfavorable impact on distant recurrence-free survival (HR 2.27 [95% confidence interval [CI] 0.98-5.25; p = 0.05] and overall survival (HR 2.61 [95% CI 1.11-6.13; p = 0.03]). After adjusting for tumor features, the HRs became 2.11 (95% CI 0.89-5.02; p = 0.09) and 2.24 (95% CI 0.92-5.45; p = 0.07), respectively. The residual 5-year rate for distant recurrence-free survival was 76.9% for women with OFR and 92.1% for women without OFR, and for 5-year overall survival 80.8% and 94.4%, respectively. Women with CIOFF receiving anastrozole may be at increased risk of disease recurrence if experiencing OFR.

Keywords: aromatase inhibitor; breast cancer; chemotherapy-induced amenorrhea; chemotherapy-induced ovarian function failure (CIOFF); ovarian function recovery (OFR).

Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients.
Jenny Jaque, Heather Macdonald, +4 authors, Frank Z Stanczyk.
Springerplus, 2013 Mar 23; 2(1). PMID: 23520572    Free PMC article.
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Clifford A Hudis, William E Barlow, +8 authors, Jo Anne Zujewski.
J Clin Oncol, 2007 May 22; 25(15). PMID: 17513820
Highly Cited.
Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
Richard J Santen, Lawrence Demers, +5 authors, Shuping Wang.
Steroids, 2007 Jun 26; 72(8). PMID: 17588628
Analysis of survival by tumor response.
J R Anderson, K C Cain, R D Gelber.
J Clin Oncol, 1983 Nov 01; 1(11). PMID: 6668489
Highly Cited.
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
J Michael Dixon, Lorna Renshaw, +7 authors, Mitch Dowsett.
J Clin Oncol, 2008 Apr 01; 26(10). PMID: 18375896
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Christina Davies, Hongchao Pan, +36 authors, Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.
Lancet, 2012 Dec 12; 381(9869). PMID: 23219286    Free PMC article.
Highly Cited.
Predictors of recovery of ovarian function during aromatase inhibitor therapy.
N L Henry, R Xia, +8 authors, D F Hayes.
Ann Oncol, 2013 Apr 25; 24(8). PMID: 23613476    Free PMC article.
Interpreting plasma estrogen levels in breast cancer: caution needed.
Elizabeth J Folkerd, Per E Lønning, Mitch Dowsett.
J Clin Oncol, 2014 Apr 16; 32(14). PMID: 24733806
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Michael Gnant, Brigitte Mlineritsch, +18 authors, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
Lancet Oncol, 2011 Jun 07; 12(7). PMID: 21641868
Highly Cited.
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
Harold J Burstein, Christina Lacchetti, +9 authors, Jennifer J Griggs.
J Clin Oncol, 2016 Feb 18; 34(14). PMID: 26884586
Highly Cited. Systematic Review.
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Ivana Sestak, Wolfgang Distler, +3 authors, Jack Cuzick.
J Clin Oncol, 2010 Jun 16; 28(21). PMID: 20547990
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Georg Pfeiler, Robert Königsberg, +13 authors, Michael Gnant.
J Clin Oncol, 2011 May 11; 29(19). PMID: 21555684
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
C Rose, O Vtoraya, +11 authors, R Lang.
Eur J Cancer, 2003 Oct 15; 39(16). PMID: 14556923
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
Poornima Saha, Meredith M Regan, +25 authors, International Breast Cancer Study Group.
J Clin Oncol, 2017 Jun 28; 35(27). PMID: 28654365    Free PMC article.
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Vivianne C G Tjan-Heijnen, Irene E G van Hellemond, +14 authors, Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators.
Lancet Oncol, 2017 Oct 17; 18(11). PMID: 29031778
Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?
Antroula Papakonstantinou, Theodoros Foukakis, Kenny A Rodriguez-Wallberg, Jonas Bergh.
J Clin Oncol, 2016 Mar 10; 34(14). PMID: 26951320
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Ian E Smith, Mitch Dowsett, +4 authors, Daniel Hayes.
J Clin Oncol, 2006 Jun 01; 24(16). PMID: 16735701
Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.
Irene E G van Hellemond, Ingeborg J H Vriens, +16 authors, Dutch Breast Cancer Research Group (BOOG).
J Natl Cancer Inst, 2018 Mar 17; 109(12). PMID: 29546343
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
M Gnant, G Pfeiler, +12 authors, R Jakesz.
Br J Cancer, 2013 Jul 23; 109(3). PMID: 23868011    Free PMC article.
Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.
A Guerrero, J Gavilá, +6 authors, A Ruíz.
Ann Oncol, 2012 Oct 31; 24(3). PMID: 23108951
The normal menopause transition.
Sonja M McKinlay, Donald J Brambilla, Jennifer G Posner.
Maturitas, 2009 May 13; 61(1-2). PMID: 19434875
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2015 Jul 28; 386(10001). PMID: 26211827
Highly Cited.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Olivia Pagani, Meredith M Regan, +32 authors, International Breast Cancer Study Group.
N Engl J Med, 2014 Jun 03; 371(2). PMID: 24881463    Free PMC article.
Highly Cited.
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Paul E Goss, James N Ingle, +18 authors, Lois E Shepherd.
J Clin Oncol, 2013 Jan 30; 31(11). PMID: 23358971    Free PMC article.
Highly Cited.
Amenorrhea from breast cancer therapy--not a matter of dose.
Sandra M Swain, Jong-Hyeon Jeong, Norman Wolmark.
N Engl J Med, 2010 Dec 03; 363(23). PMID: 21121855
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
Sandra M Swain, Jong-Hyeon Jeong, +14 authors, Norman Wolmark.
N Engl J Med, 2010 Jun 04; 362(22). PMID: 20519679    Free PMC article.
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Eric P Winer, Clifford Hudis, +19 authors, Mark R Somerfield.
J Clin Oncol, 2004 Nov 17; 23(3). PMID: 15545664
Highly Cited. Review.
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Meritxell Bellet, Kathryn P Gray, +17 authors, Meredith M Regan.
J Clin Oncol, 2016 Jan 06; 34(14). PMID: 26729437    Free PMC article.
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Marianne Ewertz, Kathryn P Gray, +14 authors, Henning T Mouridsen.
J Clin Oncol, 2012 Oct 10; 30(32). PMID: 23045588    Free PMC article.
Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
D C Johannessen, T Engan, +6 authors, P E Lonning.
Clin Cancer Res, 1997 Jul 01; 3(7). PMID: 9815789
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
LHRH-agonists in Early Breast Cancer Overview group, J Cuzick, +5 authors, R Sainsbury.
Lancet, 2007 May 22; 369(9574). PMID: 17512856
Mechanisms of aromatase inhibitor resistance.
Cynthia X Ma, Tomás Reinert, Izabela Chmielewska, Matthew J Ellis.
Nat Rev Cancer, 2015 Apr 25; 15(5). PMID: 25907219
Highly Cited. Review.
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.
Ian Smith, Denise Yardley, +14 authors, Joyce O'Shaughnessy.
J Clin Oncol, 2017 Jan 24; 35(10). PMID: 28113032
Challenges to the measurement of estradiol: an endocrine society position statement.
William Rosner, Susan E Hankinson, +2 authors, Margaret E Wierman.
J Clin Endocrinol Metab, 2013 Mar 07; 98(4). PMID: 23463657    Free PMC article.
Highly Cited. Review.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Prudence A Francis, Olivia Pagani, +34 authors, SOFT and TEXT Investigators and the International Breast Cancer Study Group.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29863451    Free PMC article.
Highly Cited.